Cell Cure Neurosciences, a fully owned subsidiary of Lineage Cell Therapeutics Inc., was founded on cutting-edge technology from Hadassah University Hospital’s Human Embryonic Stem Cell Research Center and the Departments of Ophthalmology and Neurology. Cell Cure’s leading product, OpRegen, is in a Phase I/IIa clinical trial in patients with dry AMD. In addition, Cell Cure does research and development activities for other novel therapeutics based on embryonic stem cells and GMP production of cell-based products, including OpRegen. Cell Cure is located on the campus of Hadassah University Hospital in Jerusalem, Israel.
Dr. Rami Skaliter Rami Skaliter, M.Sc., Ph.D., is the CEO of Cell Cure Neurosciences and was appointed in June 2017. In his last position, Dr. Skaliter worked for ten years as the Chief Operating Officer of Quark Pharmaceuticals, a late-stage pharmaceutical company developing siRNA-based novel therapeutics. Previously, Dr. Skaliter held various corporate and research executive positions at Quark Pharmaceuticals. Dr. Skaliter obtained his B.Sc. in Biology at the Ben-Gurion University and his M.Sc. and Ph.D. in Biochemistry at the Weizmann Institute in Israel. He specialized in the biochemistry of replication and mutagenesis mechanisms. Between 1993 and 1995, prior to joining Quark, Dr. Skaliter completed a post-doctoral fellowship at Stanford University. Dr. Skaliter serves as a director of Tikcro Technologies Ltd., a public company developing therapeutic antibodies.
Professor Reubinoff does research that is focused on human embryonic stem cells (hESCs). He derived hESC in collaboration with scientists from Monash University in Melbourne and the National University of Singapore. The group was the second in the world to derive hESC lines and was the first to show somatic differentiation of the hESCs in cultures.
Professor Banin is a key advisor at Cell Cure Neurosciences. He is the head of research into the degenerative diseases of the retina and macula, and an expert in the ﬁeld of cell therapy for those conditions.
Moshe Hukaylo, CPA, MBA, serves as the company’s CFO. He has more than 20 years of experience in finance, 15 years from within the pharmaceutical industry (Pfizer, Mercksrono). He has experience in all aspects of the pharmaceutical industry, including: biotech manufacturing, research and development, and sales and marketing. Moshe is the founder of On-Demand-CFO, a financial services consulting firm.
Sara Altman has been our company’s Finance Manager since 2011. She has extensive finance experience, which includes preparing financial reports and budgets, and taking responsibility for the grants our company receives. She previously served as a Senior CPA at Ziv Haft Deri (BDO) and was responsible for auditing the company’s financial statements. Sara is a licensed CPA and holds a B.A. in Accounting and Information Systems from Lev Academic Center and an M.A. in Accounting from Bar Ilan University.